Lucia Esposito

117P Predicting immunotherapy response in non-small cell lung cancer using a foundation model for tabular data and real-world clinical evidence: Insights from APOLLO11 study

Concetta Licciardello, Alberto Ferrarin, O. Sidelnikova, Laura Mazzeo et autres

Background: Non-small cell lung cancer (NSCLC) is one of the main causes of cancerrelated death worldwide.Immunotherapy has improved treatment options, but many patients do not respond, and the only approved biomarker, PD-L1, has limited accuracy.Better predictive tools are needed to support treatment …

it (code pays fourni par la source)

P1.11.66 Cost-Effective Machine Learning for Predicting Survival in NSCLC Patients on Immunotherapy: Insights From the APOLLO11 Study

V. Miskovic, L. Mazzeo, Carlo Silvestri, Alberto Ferrarin et autres

it (code pays fourni par la source)

351P Comprehensive genomic profiling and efficacy data in patients with advanced biliary tract cancer treated in first-line with chemo-immunotherapy combination: A real world experience

Valeria Nacca, A. Nicastro, A. Orlando, Maria Anna Canciello et autres

it (code pays fourni par la source)

11MO: AI-based prediction of long-term survival in NSCLC patients treated with immunotherapy: Insights from the multicentric APOLLO11 study

V. Miskovic, L. Mazzeo, Carlo Silvestri, Alberto Ferrarin et autres

it (code pays fourni par la source)

Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study

Carlotta Franchi, Sara Mandelli, Ilaria Ardoino, Alessandro Nobili et autres

it (code pays fourni par la source)

Minimally invasive distal pancreatectomy in obese patients: factors associated with conversion to open surgery

F. Ausania, C. González-Abós, F. Landi, J. Martinie et autres

es, us, gb, it, cn, fr (code pays fourni par la source)

620P A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data

Giulia Martini, Teresa Troiani, Davide Ciardiello, Stefania Napolitano et autres

it (code pays fourni par la source)

Correction to: Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register

Elena Succurro, Alessio Novella, Alessandro Nobili, Federica Giofrè et autres

Correction to: Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register. Succurro E, Novella A, Nobili A, Giofrè F, Arturi F, Sciacqua A, Andreozzi F, Pietrangelo A, Sesti G; REPOSI Investigators. Intern Emerg …

it (code pays fourni par la source)

Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial

Stefania Napolitano, Davide Ciardiello, Vincenzo De Falco, Giulia Martini et autres

The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression-free survival (PFS) as compared to trifluridine/tipiracil in third-line therapy in patients with refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC). With longer follow-up, final overall …

it (code pays fourni par la source)

P-227 A phase II trial evaluating the Activity of caBozantinib in pre-treated pAtients with metastatic COlorectal cancer (mCRC): ABACO trial

Giulia Martini, Teresa Troiani, Davide Ciardiello, Stefania Napolitano et autres

it (code pays fourni par la source)

SO-24 Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial

Davide Ciardiello, Stefania Napolitano, Vincenzo De Falco, Giulia Martini et autres

it (code pays fourni par la source)

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer

Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello et autres

Importance: Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients. Objective: To compare the anti-EGFR monoclonal antibody panitumumab plus …

it (code pays fourni par la source)